Chest:氢化可的松、维生素C、维生素B1对脓毒症的疗效评估

2016-12-25 haofan MedSci原创

这些研究结果表明,早期静脉注射维生素C以及加上糖皮质激素和维生素B1,可能被证明是有效的预防包括急性肾损伤在内的进行性器官功能障碍,降低严重脓毒症和感染性休克患者的死亡率。但需要更多的研究来证实这些初步的发现。

脓毒症的全球负担估计为每年有1500至1900万例患者,在低收入国家的死亡率接近60%。最近,呼吸疾病领域权威杂志Chest杂志上发表了一篇研究文章,旨在评估氢化可的松、维生素C、维生素B1对脓毒症的疗效。

在这项回顾性前后对照的临床研究中,研究人员比较了其所在重症监护室连续入院的脓毒症患者静脉注射氢化可的松、维生素C、维生素B1治疗7个月(治疗组)和7个月前该重症监护室治疗的对照者的临床过程和预后,主要结局为医院的生存率。研究人员通过倾向性得分对主要结局进行调整。

在治疗组和对照组中均有47例患者,并且两组基线特征无显著差异。治疗组医院病死率为8.5%(47例中有4例死亡),对照组为40.4%(47例中有19例死亡,P<0.001)。进行倾向性得分调整过的死亡率比值在接受维生素C治疗方案的患者为0.13(95%可信区间为0.04-0.48,P=0.002)。所有治疗组患者的SOFA评分均下降,并且无一例患者出现进展性器官衰竭。治疗组所有患者升压药使用也逐渐停用,在维生素C治疗方案开始后停用升压药的平均时间为18.3±9.8小时,而在对照组升压药使用的平均时间为54.9±28.4小时(P<0.001)。

由此可见,这些研究结果表明,早期静脉注射维生素C以及加上糖皮质激素和维生素B1,可能被证明是有效的预防包括急性肾损伤在内的进行性器官功能障碍,降低严重脓毒症和感染性休克患者的死亡率,但需要更多的研究来证实这些初步的发现。

原始出处:

Paul E. Marik,. et al. Hydrocortisone, Vitamin C and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
    2017-03-25 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
    2017-06-16 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
    2016-12-27 马龙
  7. [GetPortalCommentsPageByObjectIdResponse(id=182549, encodeId=507f182549da, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 25 07:18:50 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050574, encodeId=cd0620505e47f, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Feb 25 13:21:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915690, encodeId=549f191569057, content=<a href='/topic/show?id=2b40e04130e' target=_blank style='color:#2F92EE;'>#疗效评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70413, encryptionId=2b40e04130e, topicName=疗效评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sun Jul 30 15:21:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929264, encodeId=422319292640c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Jun 16 02:21:00 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417463, encodeId=e213141e46322, content=<a href='/topic/show?id=09ca6395150' target=_blank style='color:#2F92EE;'>#氢化可的松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63951, encryptionId=09ca6395150, topicName=氢化可的松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88b63287356, createdName=cmj9wellington, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508511, encodeId=4cd1150851157, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Tue Dec 27 10:21:00 CST 2016, time=2016-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166032, encodeId=539e1660326c, content=不错的文章。脓毒症还是人类面临的一大难题, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Tue Dec 27 10:19:03 CST 2016, time=2016-12-27, status=1, ipAttribution=)]
    2016-12-27 吴教授

    不错的文章。脓毒症还是人类面临的一大难题

    0

相关资讯

J Clin Endocrinol Metab:氢化可的松对血压的影响

背景:继发性肾上腺皮质功能不全(SAI)患者心血管风险的增加,可能归因于随之相对高剂量氢化可的松替代的不利的代谢影响。目的:探究较高的和较低的糖皮质激素替代治疗剂量对血压(BP)、肾素-血管紧张素-醛固酮系统(RAAS)、11β-羟类固醇脱氢酶(11βHSD)酶活性和(去甲)肾上腺素循环的影响。方法:格罗宁根大学医疗中心的47名患者参加了这项随机双盲交叉研究。患者随机接受0.2-0.3毫克/公斤体

JAMA:一直以来建议的氢化可的松预防脓毒性休克,真的有效吗?

拯救脓毒症运动建议难治性感染性休克患者可使用辅助性氢化可的松治疗。但目前氢化可的松在严重脓毒症无休克患者中的疗效仍有争议。来自德国的研究人员开展了一项研究,该研究旨在确定在严重脓毒症患者中,氢化可的松治疗是否能够预防脓毒性休克的发展。该双盲,随机临床试验于2009年1月13日至2013年8月27日期间进行,随访期为180天,直至2014年2月23日。该试验在德国的34家大学和社区医院的中级或重症监

Lancet:低剂量氢化可的松可预防极早产儿的支气管肺发育不良

支气管肺发育不良,是极早产的主要并发症,治疗选择很少。产后类固醇的使用是有争议的,但低剂量的氢化可的松可以防止炎症对肺发育的有害影响。在这项研究中,该研究的目的是评估低剂量氢化可的松是否提高无支气管肺发育不良极早产儿的生存率。这项双盲,安慰剂对照的随机试验在21个法国三级护理新生儿重症监护病房(NICUs)进行,研究人员通过一个安全的研究网站随机分配(1:1)极度早产的婴儿(出生在和NICU一样的

Ann Surg:围手术期使用氢化可的松,能减少胰十二指肠切除术后并发症

本研究的目的是探讨,氢化可的松是否可以减少高危患者的胰十二指肠切除术后并发症(PPDC)。软胰腺是一个知名的PPDC的风险因素。此前,我们已经表明,胰腺横断线> 40%腺泡的患者最容易发展为PPDC。最近的研究表明,手术创伤导致残留胰腺的炎症,会促进PPDC的发生。在动力分析的基础上,随机对照试验(RCT)(NCT01460615),纳入155例(2012年2月至2015年3月)拟行胰十二指

JAMA:氢化可的松能预防脓毒症患者感染性休克的发展吗?

辅助氢化可的松治疗无休克的严重脓毒症患者,疗效如何?本研究的目的是,评估氢化可的松治疗能否预防严重脓毒症患者感染性休克的发展。本项双盲、随机临床试验时间为2009年1月13日-2013年8月27日,随访180天,直到2014年2月23日。包括380名成人重度脓毒症患者,没有感染性休克。患者按1:1被随机分配为持续输注氢化可的松200毫克,5天之后,剂量逐渐减少直到11天(n = 190)或安慰剂(

JAMA:加压素-肾上腺素联用可改善心搏骤停患者出院生存

希腊一项研究表明,在需血管升压药治疗的心搏骤停患者中,心肺复苏(CRP)期间联合应用加压素-肾上腺素以及复苏后休克中应用氢化可的松可改善神经转归良好的出院生存率。论文发表于《美国医学会杂志》[JAMA.2013;310(3):270]。 此项随机双盲安慰剂对照研究共纳入268例依据复苏指南需肾上腺素治疗的心搏骤停患者,并在前5个CRP周期给予加压素联合肾上腺素(VSE组,n = 130)或生理盐